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Digestion of the glycosaminoglycan
extracellular matrix by chondroitinase ABC
supports retinal ganglion cell dendritic
preservation in a rodent model of
experimental glaucoma
James R. Tribble1,2* , Pete A. Williams2, Bruce Caterson3, Frank Sengpiel3 and James E. Morgan1,4
Abstract
Retinal ganglion cell dendritic atrophy is an early feature of glaucoma, and the recovery of retinal ganglion cell
dendrites is a viable option for vision improvement in glaucoma. Retinal ganglion cell neurites are surrounded by a
specialised glycosaminoglycan extracellular matrix which inhibits dendritic plasticity. Since digestion of the
extracellular matrix by chondroitinase ABC has been reported to have neuro-regenerative and neuro-plastic effects
within the central nervous system, we explored its potential for dendritic recovery in a rat model of ocular
hypertension. Chondroitinase ABC was administrated intravitreally 1 week after ocular hypertension (a time point
where dendritic atrophy has already occurred). Retinal ganglion cell dendritic morphology was unaffected by
chondroitinase ABC in normal retina. In ocular hypertensive eyes retinal ganglion cells showed significantly
decreased dendritic length and area under the Sholl curve with atrophy confined to higher order dendrites. These
changes were not observed in chondroitinase ABC injected eyes despite similar total retinal ganglion cell loss (i.e.
dendritic protection of surviving retinal ganglion cells). These data suggest that glycosaminoglycan digestion could
have a therapeutic role in mitigating the effects of elevated pressure on retinal ganglion cell dendritic structure in
glaucoma.
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Main text
Glaucoma is a common, age-related, neurodegeneration
characterised by the progressive atrophy and death of ret-
inal ganglion cells (the output neuron of the retina). Den-
dritic atrophy is an early feature of neuronal damage,
which has been demonstrated in a number of experimen-
tal animal glaucoma models [1–3] and offers an attractive
therapeutic window in which neuro-regenerative treat-
ments could restore dendritic connectivity and rescue vi-
sion. However, the adult central nervous system has
limited plasticity, particularly following injury [4]. The
extracellular matrix surrounding neurons in the central
nervous system plays a dynamic role in synaptic refine-
ment in the critical period, guiding neurite outgrowth be-
fore stabilising favourable connections at its closure [5]. It
comprises a hyaluronan backbone, proteoglycan lectican
family side chains with glycosaminoglycan (GAG) attach-
ments of varying length and composition [6]. Chondroitin
sulphate is a common GAG chain that has demonstrated
inhibition of plasticity [7]. When removed through en-
zymatic digestion with chondroitinase ABC, synaptic plas-
ticity has been enhanced in a number of conditions
including shifting ocular dominance [8] and striatal
re-innervation following nigrostriatal axotomy [9]. We
therefore hypothesized that chondroitinase ABC treat-
ment following glaucomatous degeneration could enable
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Fig. 1 Chondroitinase ABC protects dendritic architecture following ocular hypertension. a Microbead injections produced 2–3 weeks of raised
IOP; average profiles with shaded SD shown. b The AUC of IOP profiles shows a significantly greater IOP in OHT groups compared to NT UOC.
Chondroitinase ABC had no effect on IOP post injection. c Cell loss was assessed by TOPRO-3 counts; example images shown. d OHT resulted in
significant cell loss in the GCL compared to NT UOC; cell loss was not significantly different between OHT groups. e Dendritic morphology was
assessed following DiOlistic labelling; example cells from each group shown. f Sholl profiles demonstrate that chondroitinase ABC injection in NT
ABC eyes had no effect on dendritic complexity (left). OHT PBS eyes showed a reduced complexity (statistical values shown in table below plot
for NT UOC against OHT PBS) that was rescued by chondroitinase ABC injection (right). Analysis of dendritic morphology revealed a significant
reduction in OHT PBS retinal ganglion cells compared to in NT UOC for metrics of Sholl AUC (g), branching index (h), total dendritic length and
distal dendritic length (i). j Dendritic field area was unchanged across groups, indicating reduced density of branches. k Retinal ganglion cell
eccentricity had no effect on dendrite morphology, with cells analyzed across all regions (optic nerve head at x = 0, y = 0; group colors as in F-J).
Multivariate regression analysis showed no significant correlation between the distance from optic disc and the outcome variables (Sholl AUC: R2
0.0018, P = 0.25; Sholl BI: R2–0.0026, P = 0.47; dendritic field area: R2 0.0993, P = 0.01, total dendritic length: R2 0.0033, P = 0.56, proximal dendritic
length: R2 0.0087, P = 0.10, and distal dendritic length: R2 0.0195, P = 0.03). * = P < 0.05, ** = P < 0.01, *** = P < 0.001. Scale bars = 50 μm for (c),
100 μm for (e). For box plots, center hinge represents the mean and the upper and lower hinges represent the first and third quartiles; whiskers
represent 1.5 times the interquartile range
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sufficient retinal plasticity for a re-growth of retinal gan-
glion cell dendrites.
To assess retinal ganglion cell dendritic architecture,
we used a rat inducible model of experimental glaucoma
in which para-magnetic microbeads were injected into
the anterior chamber, and distributed circumferentially
with an externally applied magnet to block aqueous
humour drainage and elevate intraocular pressure (IOP).
Pressure increases typically last 2–3 weeks by which
point significant retinal ganglion cell dendritic degener-
ation has occurred [10, 11]. The left anterior chambers
of 19 Brown Norway rats (5 months old) were injected
with 30mg/ml (4.7 × 105 particles) of para-magnetic
polystyrene microspheres (4.5 μm diameter, Kisker Bio-
technology, Germany) as described by Samsel et al. [10]
generating ocular hypertensive eyes (OHT). The IOP
was measured before injection and every 3 days subse-
quently using a rebound tonometer (Tonolab, Icare,
Finland). After the return of the IOP to baseline for the
period of 1 week, rats received an intravitreal injection
in the OHT eye of either: 3 μl chondroitinase ABC (10
U/ml in PBS, from Proteus vulgaris, AMS Biotechnology,
UK; n = 9, OHT ABC group) or vehicle only (1M PBS,
n = 10, OHT PBS group). A further 7 rats that were not
induced with experimental glaucoma received an intra-
vitreal injection of chondroitinase ABC (10 U/ml in PBS,
NT ABC group). All contralateral eyes provided a
normotensive un-operated control (NT UOC, n = 26).
The effect of treatment was assessed 2 weeks after intra-
vitreal injection, allowing sufficient time for dendritic re-
covery. We confirmed chondroitinase ABC action
through immunofluorescent labelling of digested chon-
droitin sulphate GAGs (2B6 antibody [6]) in the gan-
glion cell layer (GCL; Additional file 1: Figure S1). Eyes
were enucleated and retinas flat mounted. Retinal gan-
glion cells were labelled DiOlistically as described previ-
ously [11]. Z-stack confocal images were acquired and
dendritic arbours traced manually using NeuronJ [12] in
FIJI [13]. TOPRO-3 cell counts were performed on 4 re-
gions of the GCL (100 μm2 en face area, 1500 μm from
the optic disc nasally, temporally, superiorly and infer-
iorly) and averaged. Statistical analysis was performed in
R; all tests are one-way ANOVA with Tukey HSD.
OHT eyes demonstrated increased IOPs for 2–3 weeks
(mean ± SD = 20 ± 5 days for OHT PBS, 18 ± 4 days for
OHT ABC; Fig. 1a) which was significantly greater (IOP
area under curve (AUC)) than contralateral controls
(NT UOC; P < 0.001 for OHT PBS, < 0.001 for OHT
ABC; Fig. 1b). Chondroitinase ABC injection alone had
no effect on IOP (AUC, P = 0.972). Cell counts revealed
a significant decrease in cells in the GCL in both OHT
PBS (21% loss, P < 0.001) and OHT ABC-treated eyes
(26% loss, P < 0.001) when compared to contralateral
control eyes (Fig. 1c-d). The degree of cell loss was not
significantly different between OHT PBS and OHT ABC
(P = 0.197) indicating comparable IOP induced damage.
Analysis of dendritic trees revealed that chondroitinase
ABC conferred a significant protection of dendrites in
glaucoma (Fig. 1e for representative cells). Sholl analysis
(a measure of dendrite frequency at binned distance
from the soma, Fig. 1f ) revealed a reduced dendritic
complexity in OHT PBS as demonstrated by significantly
fewer dendrites at distances of 100-160 μm from the
soma centre (P < 0.05, see Fig. 1f for individual values).
These Sholl changes were also confirmed when
expressed as an AUC (P = 0.014; Fig. 1g) and as a
branching index (branching events weighted by distance
from soma, [14]; P < 0.001; Fig. 1h). This dendritic atro-
phy was not observed in OHT ABC (AUC P = 0.578,
branching index P = 0.086). Total dendritic length was
decreased in OHT PBS (P = 0.006) but not OHT ABC
(P = 0.365) compared to NT UOC (Fig. 1i). Analysis of
individual dendrites revealed that this was confined to
the distal dendrites (quaternary and above; P < 0.001)
with no changes in proximal dendrites (primary, second-
ary, tertiary; P = 0.901). Dendritic field area was un-
changed between groups; dendrite loss in the absence of
filed size changes is indicative of a loss of dendritic dens-
ity (Fig. 1j). Retinal ganglion cells were sampled evenly
across the retina (Fig. 1k) and thus the eccentricity did
not impact morphological comparisons.
These data demonstrate moderate dendritic preserva-
tion in ocular hypertensive eyes following chondroitinase
ABC treatment. Further studies in which single cells are
followed longitudinally over time are required to con-
firm whether this is a protective or regenerative effect.
Since it is well established that dendritic loss occurs early
during ocular hypertensive insult [3], and as we have previ-
ously reported significant dendritic loss in this model after
2 weeks of raised IOP [11] the delayed nature of the treat-
ment in this experimental paradigm is suggestive of a re-
growth of dendrites, however, additional time points are
required to fully assess this.. Removal of chondroitin
sulphate GAG chains may therefore have increased the
plastic potential of the retina following injury and may be
of therapeutic benefit in glaucoma. In a recent study, the
use of Arylsulfatase B to cleave only inhibitory 4-sulphated
chondroitin sulphate chains facilitated increased axon out-
growth following optic nerve crush [15]. Therefore a more
targeted removal of chondroitin sulphate chains may prove
to be more efficacious in glaucoma.
Additional file
Additional file 1: Figure S1. Chondroitinase ABC action in the GCL.
Chondroitinase ABC digestion of chondroitin sulphate GAG sidechains
leaves ‘stubs’ that can be targeted by immunofluorescent labelling of
cryosections. Digestion to a sulphation residue exposes antibody binding
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sites for 2-B-6 (targeting 4-sulpahted N-acetylgalactosamine). 2-B-6 label-
ling (green) is clear surrounding cells in the GCL (white; nuclei stained
with Hoechst-33,342) in chondroitinase ABC injected eyes (OHT ABC) and
is absent in OHT PBS and negative controls sections (2° antibody only).
Choroid incubated with chondroitinase ABC ex vivo is used as a positive
control, in which 2-B-6 labelling is clear. Scale bar = 50 μm for retinal
sections, 25 μm for choroid section. (TIF 5737 kb)
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